The growing knowledge of HαT and eventually the increasingly wider use of genotyping in clinical practice could contribute to improving the diagnosis of SM, downsizing the confounding factor of high BST levels in patients with an unclear presentation of a clonal MC disorder. This evidence concerns the gene TMPRSS11D and systemic mastocytosis.